Unicycive Therapeutics, Inc. (UNCY)
NASDAQ: UNCY · IEX Real-Time Price · USD
1.040
+0.010 (0.97%)
At close: May 17, 2024, 4:00 PM
1.010
-0.030 (-2.88%)
After-hours: May 17, 2024, 7:49 PM EDT
Company Description
Unicycive Therapeutics, Inc., a biotechnology company, develops treatments for various medical conditions in the United States.
Its drug candidates include UNI 494, a pro-drug of Nicorandil that is being developed as a treatment for acute kidney injury; and Renazorb (Oxylanthanum Carbonate), which is being developed for the treatment of hyperphosphatemia in patients with chronic kidney disease.
Unicycive Therapeutics, Inc. has license agreements with Shilpa Medicare Ltd; Sphaera Pharma Pte. Ltd.; Syneos Health LLC; Inotiv; Lee's Pharmaceutical (HK) Limited; Celerion; and Lotus International Pte Ltd. The company was incorporated in 2016 and is based in Los Altos, California.
Unicycive Therapeutics, Inc.
Country | United States |
Founded | 2016 |
IPO Date | Jul 13, 2021 |
Industry | Biotechnology |
Sector | Healthcare |
Employees | 14 |
CEO | Dr. Shalabh K. Gupta M.D., MPA |
Contact Details
Address: 4300 El Camino Real, Suite 210 Los Altos, California 94022 United States | |
Phone | 650-384-0642 |
Website | unicycive.com |
Stock Details
Ticker Symbol | UNCY |
Exchange | NASDAQ |
Fiscal Year | January - December |
Reporting Currency | USD |
IPO Price | $5.00 |
CIK Code | 0001766140 |
CUSIP Number | 90466Y103 |
ISIN Number | US90466Y1038 |
Employer ID | 81-3638692 |
SIC Code | 2834 |
Key Executives
Name | Position |
---|---|
Dr. Shalabh K. Gupta M.D., MPA | Founder, Chairman, Chief Executive Officer and President |
Dr. Pramod Gupta Ph.D. | Executive Vice President of Pharmaceutical and Business Operations |
Douglas Jermasek M.B.A. | Executive Vice President of Corporate Strategy |
John W. Townsend CPA | Chief Financial Officer |
Latest SEC Filings
Date | Type | Title |
---|---|---|
May 13, 2024 | 8-K | Current Report |
May 13, 2024 | 10-Q | Quarterly Report |
May 8, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
Apr 26, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
Apr 26, 2024 | ARS | Filing |
Apr 26, 2024 | DEF 14A | Other definitive proxy statements |
Apr 16, 2024 | PRE 14A | Other preliminary proxy statements |
Mar 29, 2024 | 8-K | Current Report |
Mar 28, 2024 | 10-K | Annual Report |
Mar 20, 2024 | D | Notice of Exempt Offering of Securities |